← BioTransfer GEO Dataset Finder
GEO series

Augment proteasome inhibitor efficacy activates CD8+ T cell-mediated antitumor immunity in breast cancer

GSE296112 Mus musculus (mouse) RNA-seq (gene expression) 27 samples Submitted 2025/05/01 Platform GPL34281Platform GPL34328
At a glance

RNA-seq (gene expression) · mouse · 27 samples

What it is
RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
Organism
Mus musculus (mouse)
Topic
Breast cancerThis series is part of our curated briefing on it.
Samples
27 samples: 9 conditions, mostly in triplicateGroups are read from the sample names, not from the paper. Check the list below.
Data you can get
A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Paper
Augment proteasome inhibitor efficacy activates CD8(+) T cell-mediated antitumor immunity in breast cancerCell reports. Medicine · 2025
Summary (written by the submitters)
Although three proteasome inhibitors have been used for liquid tumor treatment, their effectiveness against solid tumors remains inadequate. To address this issue, we employed a drug combination strategy and discovered that ammonium tetrathiomolybdate (TM) and AMD3100 can sensitize solid cancer cell lines to proteasome inhibitors. Mechanistically, we found that TM and AMD3100 reduce proteasome activity by decreasing the protein level of PSMB5.
Read the full summary ↓
This reduction occurs through the activation of the AMPK pathway, which inhibits STAT3 phosphorylation. Notably, our in vivo studies revealed that drug combinations retarded tumor growth dependent on CD8+ T cells. The combination of bortezomib with TM or AMD3100 induced cancer cell antigen presentation and the production of CCL5, which together stimulated the recruitment and generation of cytotoxic CD8+ T cells. This study identifies new synergistic lethal pairs that enhance the effectiveness of bortezomib-centered therapy against breast cancer.
Published in
Augment proteasome inhibitor efficacy activates CD8(+) T cell-mediated antitumor immunity in breast cancer
Tang D, Lin S, Zhou J et al. · Cell reports. Medicine 2025 · PMID 40609539 · doi:10.1016/j.xcrm.2025.102211
This dataset
Open GSE296112 in finder → Find more RNA-seq datasets → Breast cancer landscape →
Download · which file do I need?

Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.

1 · Just have a look

Processed table

The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.

Series matrix ↓
2 · Re-analyse it

Supplementary files

The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE296112_RAW.tar (it can run to tens of gigabytes).

All supplementary files ↗ Whole study · RAW.tar ↓
3 · Start from the raw reads

Raw sequencing reads

The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.

Raw reads on ENA ↗

What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.

Also filed as BioProject PRJNA1257810 and SRA study SRP582590. Searching any of these in the dataset finder brings you back here.

NCBI GEO page ↗ Paper (PMID 40609539) ↗
Study design
9 conditions, mostly in triplicate
HCC1937-vehicle ×3 HCC1937-TM ×3 HCC1937-AMD3100 ×3 MDA-MB-231-vehicle ×3 MDA-MB-231-Bortezmib+TM ×3 MDA-MB-231-Bortezmib+AMD3100 ×3 4T1-vehicle ×3 4T1-Bortezmib+TM ×3 +1 more

Supports a between-group comparison across 27 samples.

How we read this: 9 replicated groups read from 27 sample titles; they account for 27 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.

Samples in this study
More Breast cancer datasets

Search all RNA-seq datasets in GEO →

Share this dataset

Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.